In line with our experimental data, the bioinformatic analysis revealed that ITGA6 and ITGB4 expression levels negatively correlated with both metastatic disease and a worse prognosis for biochemical recurrence indicating a progressive disease in patients with low PTEN level (Fig. 3O–R, Fig. S8) and low levels of either ITGA6 or ITGB4. Importantly, in patients with PTEN copy loss reduction of ITGB4 or ITGA6 expression significantly increased PCa aggressiveness (Fig. S9). Here, ITGB4 is linked to posterior cortical atrophy.